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ESR1 and endocrine therapy resistance:
more than just mutations
Estrogen receptor (ER)-positive breast cancer accounts for 70%–
80% of all diagnosed breast cancers [1]. The adoption of endo-
crine therapies, including ER modulators/degraders (SERMs/
SERDs), which antagonize ER, and aromatase inhibitors (AIs),
which suppress estrogen synthesis, as the mainstay of treatment
of ER-positive breast cancer patients has resulted in substantial
survival benefit for patients with early stage disease [2]. Treating
ER-positive metastatic breast cancer (MBC), however, remains a
significant clinical challenge, due to the development of second-
ary resistance to all modalities of endocrine therapy [3]. Recently,
studies have identified recurrent somatic mutations within the
ligand-binding domain (LBD) of ESR1 (encoding ER) in>30%
of ER-positive MBC [4–8]. These mutations alter the conform-
ation of ER and produce a constitutively active form of the pro-
tein. Mutations at residues 536–538, in particular, promote ER
activity in the absence of ligand, resulting in resistance to AIs and
reduced sensitivity to SERMs/SERDs [4, 5]. ESR1 fusion genes
have also been reported in ER-positive MBCs; however, a detailed
description of their manifestations and clinical prevalence is lack-
ing [9]. In this issue of Annals of Oncology, Hartmaier et al. re-
ported the identification of recurrent hyperactive ESR1 fusion
genes in breast cancers resistant to endocrine therapy [10], add-
ing to the diversity of reported ESR1 alterations.
Hartmaier et al. carried out a retrospective study to discover
genomic rearrangements involved in the acquired resistance to
ER-targeted therapies [10]. Using mate-pair DNA sequencing
and/or RNA sequencing of matched primary-metastasis-normal
samples from 6 patients, the authors identified an ESR1-DAB2
in-frame fusion transcript that fused exons 1–6 of ESR1 to exons
3–15 of DAB2. This fusion was found only in the lymph node me-
tastasis but not in the primary. RNA sequencing analysis of an
additional 51 breast cancer metastases revealed an ESR1-GYG1
fusion gene in a bone metastasis, comprising the ESR1 exons 1–6,
the same involved in the ESR1-DAB2 fusion gene, and the 30 end
of GYG1. Importantly, both fusions were also detectable at the
protein level [10].
Prompted by the discovery of recurrent ESR1 fusion break-
points, the authors analyzed 9542 breast cancers (including 5216
from metastases) and 254 circulating tumor DNA (ctDNA) sam-
ples from advanced breast cancer patients, and identified 7 add-
itional ESR1 fusion genes. Including the initial cohorts subjected
to mate-pair and/or RNA sequencing, 5 fusions were identified in
metastatic disease (5/5, 272, 0.09%), 1 in local recurrence after
endocrine therapy (1/4, 329, 0.02% of primary tumors) and 3 in
ctDNA (3/254, 1.2%). For the 4/9 patients with available clinical
histories, all had been treated extensively with AIs. Of note, the
ESR1 breakpoints were all in or between exons 6 and 7, disrupting
the LBD of ESR1. In vitro analysis of 3 of the fusions identified
(ESR1-DAB2, ESR1-GYG1, and ESR1-SOX9) demonstrated that
all had ligand-independent activity and two were hyperactive
[10]. These observations suggest a potential role for the distinct 30
gene partners in determining resultant ER activity.
With genomic breakpoints frequently located in intronic re-
gions, capture-based targeted sequencing of exons does not al-
ways detect fusion genes. Structural rearrangements, however,
are frequently associated with copy number alterations. Based on
this notion, the authors devised a novel algorithm copyshift to de-
tect intra-genic fusion junctions associated with copy number
changes in targeted sequencing. When tested in a cohort of lung
cancer with known ALK rearrangements, the authors showed
that copyshift was specific (>89% positive predictive value), albeit
with limited sensitivity (85% false negative rate). Applying
copyshift to the cohort of 9542 breast cancers to interrogate the re-
current ESR1 breakpoint region, the authors found 83 copyshift-
positive tumors. These tumors were enriched for ER-positive and
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metastatic disease, and were associated with the presence of acti-
vating ESR1 mutations. Taken together, the authors estimated
that at least 1% of MBCs harbored ESR1 fusion genes. With the
85% false negative rate of copyshift, the prevalence of 1% may rep-
resent an underestimate, since copyshift prioritizes specificity
over sensitivity.
The discovery of recurrent ESR1 fusion genes reinforces the con-
cept that resistance to targeted therapies often represents a conver-
gent phenotype (i.e. that resistance, the phenotype observed,
may be caused by distinct genetic alterations) [11]. In the case of
resistance to endocrine therapy, the identification of recurrent re-
arrangements adds to the previously described activating muta-
tions to expand the repertoire of genetic alterations affecting ESR1
(Figure 1). A similar phenomenon has been described for resist-
ance to PARP inhibitors/platinum salts in BRCA1/2 germline mu-
tation carriers, with distinct BRCA1/2 intragenic deletions or
reversion mutations [12–14] restoring the reading frame and thus
resulting in resistance. In fact, multiple activating ESR1 mutations
have been detected in the ctDNA samples of patients harboring acti-
vating ESR1 fusion gene [10], suggesting the existence of polyclonal
resistance mechanism, akin to the recent reports of polyclonal
BRCA1/2 reversion mutations in therapy-resistant patients [15, 16].
The results reported by Hartmaier et al. [10] have important
and immediate clinical implications. The emergence of ESR1 mu-
tations as a resistance mechanism to AIs has led to the develop-
ment of novel molecules and combination regimens that are
more effective in suppressing ESR1-mutant tumor growth [17–
19]. Even these new agents and regimens, however, rely on target-
ing the LBD. The loss of the LBD by genomic rearrangements
may represent a resistance mechanism not readily detectable by
common approaches such as ddPCR/BEAMing and targeted
sequencing of exonic regions, arguing for the use of methods
such as copyshift or RNA sequencing based methods to identify
such alterations. It should be noted, however, that the biological
and clinical significance of the findings by Hartmaier et al. [10]
remains to be fully elucidated, given that limited clinical history
was available. Furthermore, the authors demonstrated the detec-
tion of the chimeric proteins in only a handful of patients and it is
possible that some of the ESR1 fusion genes are not transcribed
and/or translated, or may have limited impact on the resistance
to endocrine therapies. It would be important to investigate the
mutual exclusivity or co-occurrence between ESR1 mutations
and/or fusions and other mechanisms of resistance [20–23] and
the existence of multiple subclonal resistance mechanisms in in-
dividual patients, and whether the mechanisms resulting in the
acquisition of distinct modalities of resistance to endocrine ther-
apy would differ.
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Figure 1. Development of resistance to estrogen suppression via distinct somatic genetic alterations in the ESR1 gene. Structural/functional representation of the somatic genetic alterations in
ESR1 leading to resistance to estrogen suppression in breast cancer. The structural domains of the ESR1 gene are shown in different colors, including the transcription activation function 1
(AF-1) domain, the DNA-binding zinc finger, C4 type domain (zf), ligand-binding domain (LBD), and the nuclear receptor C-terminal domain (NR). The positions of the coding exons 3–10 are
illustrated beneath the protein domains. Whilst wild-type ESR1 consists of intact coding exons 3–10, ESR1 fusion genes and/or hotspot activating mutations disrupt the ligand-binding
domain.
Editorials Annals of Oncology









effentliche Bibliotherk der U
niversitÃ¤t Basel) user on 28 January 2019
15-year survival: an overview of the randomised trials. Lancet 2005; 365:
1687–1717.
2. Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as thera-
peutic targets in breast cancer. Curr Top Med Chem 2006; 6(3):
181–202.
3. Strasser-Weippl K, Goss PE. Advances in adjuvant hormonal therapy for
postmenopausal women. J Clin Oncol 2005; 23(8): 1751–1759.
4. Robinson DR, Wu YM, Vats P et al. Activating ESR1 mutations in
hormone-resistant metastatic breast cancer. Nat Genet 2013; 45(12):
1446–1451.
5. Toy W, Shen Y, Won H et al. ESR1 ligand-binding domain mutations in
hormone-resistant breast cancer. Nat Genet 2013; 45(12): 1439–1445.
6. Zehir A, Benayed R, Shah RH et al. Mutational landscape of metastatic
cancer revealed from prospective clinical sequencing of 10, 000 patients.
Nat Med 2017; 23(6): 703–713.
7. Chandarlapaty S, Chen D, He W et al. Prevalence of ESR1 Mutations in
Cell-Free DNA and Outcomes in Metastatic Breast Cancer: a Secondary
Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 2016; 2(10):
1310–1315.
8. Schiavon G, Hrebien S, Garcia-Murillas I et al. Analysis of ESR1
mutation in circulating tumor DNA demonstrates evolution during
therapy for metastatic breast cancer. Sci Transl Med 2015; 7(313):
313ra182.
9. Li S, Shen D, Shao J et al. Endocrine-therapy-resistant ESR1 variants re-
vealed by genomic characterization of breast-cancer-derived xenografts.
Cell Rep 2013; 4(6): 1116–1130.
10. Hartmaier RJ, Trabucco SE, Priedigkeit N et al. Recurrent hyperactive
ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann
Oncol 2018; 29(4): 872–880.
11. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer pro-
gression and treatment. Cell 2011; 145(1): 30–38.
12. Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by
intragenic deletion in BRCA2. Nature 2008; 451(7182): 1111–1115.
13. Sakai W, Swisher EM, Karlan BY et al. Secondary mutations as a mechan-
ism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;
451(7182): 1116–1120.
14. Swisher EM, Sakai W, Karlan BY et al. Secondary BRCA1 mutations in
BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer
Res 2008; 68(8): 2581–2586.
15. Weigelt B, Comino-Mendez I, de Bruijn I et al. Diverse BRCA1 and
BRCA2 reversion mutations in circulating cell-free DNA of therapy-
resistant breast or ovarian cancer. Clin Cancer Res 2017; 23(21):
6708–6720.
16. Christie EL, Fereday S, Doig K et al. Reversion of BRCA1/2 germline mu-
tations detected in circulating tumor DNA from patients with high-
grade serous ovarian cancer. JCO 2017; 35(12): 1274–1280.
17. Bihani T, Patel HK, Arlt H et al. Elacestrant (RAD1901), a selective estro-
gen receptor degrader (SERD), has antitumor activity in multiple ER(þ)
breast cancer patient-derived xenograft models. Clin Cancer Res 2017;
23(16): 4793–4804.
18. Wardell SE, Ellis MJ, Alley HM et al. Efficacy of SERD/SERM hybrid-
CDK4/6 inhibitor combinations in models of endocrine therapy-
resistant breast cancer. Clin Cancer Res 2015; 21(22): 5121–5130.
19. Weir HM, Bradbury RH, Lawson M et al. AZD9496: an oral estrogen re-
ceptor inhibitor that blocks the growth of ER-positive and ESR1-mutant
breast tumors in preclinical models. Cancer Res 2016; 76(11):
3307–3318.
20. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in
tamoxifen-resistant breast cancer: relationship between estrogen recep-
tor, HER-2, and p38 mitogen-activated protein kinase. JCO 2005;
23(11): 2469–2476.
21. Jirstrom K, Stendahl M, Ryden L et al. Adverse effect of adjuvant tamoxi-
fen in premenopausal breast cancer with cyclin D1 gene amplification.
Cancer Res 2005; 65(17): 8009–8016.
22. Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be
acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004;
101(25): 9393–9398.
23. Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endo-
crine therapy resistance and is a therapeutic target in breast cancer.
Cancer Res 2010; 70(5): 2085–2094.
doi:10.1093/annonc/mdy081
Published online 7 March 2018
Genetic profiling of cell-free DNA from
cerebrospinal fluid: opening the barrier to
leptomeningeal metastasis in EGFR-mutant
NSCLC
Over the past decade, remarkable progress has been made in the
management of advanced non-small-cell lung cancer (NSCLC),
when tyrosine kinase inhibitors (TKIs) and immune checkpoint
inhibitors have been added to the therapeutic armamentarium.
Indeed, dramatic responses to epidermal growth factor receptor
(EGFR)-TKIs are observed in patients with NSCLC harbouring
activating EGFR driver mutations [1, 2]. Unfortunately, all tu-
mours ultimately develop secondary resistance, half of these due
to the acquirement of the gatekeeper EGFR T790M mutation [3].
Fortunately, T790M-induced resistance can now be successfully
addressed by use of third-generation EGFR-TKIs that show im-
pressive activity in these patients [4].
Despite the much better outcome of patients with EGFR-mutant
NSCLC nowadays, central nervous system metastases, and in par-
ticular leptomeningeal metastases (LM), remain a devastating
complication associated with a poor prognosis and often dramatic
effect on quality-of-life [5]. Particularly in EGFR-mutant NSCLC,
LM appears to occur more frequently with a reported incidence of
9.4% [6]. Information regarding the genetic profile of LM is largely
lacking, as these lesions are hard to access. Consequently, little pro-
gress has been made in the management of LM disease. Due to re-
cent technological advances, it is now possible to study genetic
alterations in widely accessible but relatively challenging sources of
tumour DNA, such as circulating cell-free tumour DNA (ctDNA)
in plasma or in cerebrospinal fluid (CSF) [7, 8]. This is an import-
ant evolution as the detection of tumour-specific mutations in the
CSF may increase the diagnostic sensitivity and specificity of LM,
allow monitoring of treatment response and improve our under-
standing of the evolving tumour biology.
In this issue of Annals of Oncology, Li et al. report that CSF-
derived ctDNA is a valuable source of tumour DNA, allowing the
identification of the unique genetic profile of LM in EGFR-mu-
tant NSCLC. In their study, ultra-deep targeted next-generation
sequencing (NGS) analysis was carried out on different sources of
tumour DNA obtained from 26 NSCLC patients diagnosed with
LM and carrying EGFR driver mutations in their primary tu-
mour. DNA sources included cell-free DNA obtained from CSF
and plasma, as well as cellular DNA obtained from CSF precipi-
tates and primary tumour tissue [9]. Of interest, apart from single
nucleotide variants and small insertions and deletions (indels),
also copy number alterations (CNAs) were investigated.
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